| [November 13, 2014] |
 |
Tolero Pharmaceuticals Presents Positive Preclinical Data on Programs in Leukemia and Anemia at the 56th ASH Annual Meeting and Exposition
SALT LAKE CITY --(Business Wire)--
Tolero
Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company
developing treatments for oncology and hematologic diseases, announced
today that it will present two oral and two poster presentations at the
56th American Society of Hematology (ASH) Annual Meeting in
San Francisco, California, December 6-9, 2014. The presentations include
preclinical proof-of-concept of Tolero's Axl kinase inhibitors for the
treatment of leukemias and ALK2 inhibitors, which regulate hepcidin, for
the treatment of anemia.
Details of the oral presentations are as follows:
Abstract: #212
Title: Novel
Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential
Therapeutics for Anemia of Chronic Disease
Presenter: Steven
L. Warner, PhD
Session Title: 102. Regulation of Iron
Metabolism: Iron-restrictive Anemias - New Pathways and Therapeutic
Strategies
Date: Monday, December 8, 2014, 7:15 AM PT
Location:
Yerba Buena Ballroom Salon 9 (San Francisco Marriott Marquis)
Abstract: #831
Title: Axl
Regulates Fibroblast Growth Factor Receptor Signaling in B-Cell Chronic
Lymphocytic Leukemia: Dual Targeting in CLL Therapy
Presenter:
Sutapa Sinha
Session Title: 641. CLL: Biology and
Pathophysiology, excluding Therapy: Novel Prognosticators and
Therapeutic Targets
Date: Tuesday, December 9, 2014, 8:00 AM
PT
Location: South Building, Esplanade 302 (Moscone Center)
Details of the poster presentations are as follows:
Abstract: #1946
Title: Targeted
Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for
Apoptosis: Synergistic/Additive Effects in Combination with Bruton's
Tyrosine Kinase Inhibitors
Presenter: Sutapa Sinha
Session
Title: 641. CLL: Biology and Pathophysiology, excluding Therapy:
Poster I
Date: Saturday, December 6, 2014, 5:30 PM-7:30 PM PT
Location:
West Building, Level 1 (Moscone Center)
Abstract: #2350
Title: The
Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted
Therapy in Acute Myeloid Leukemia
Presenter: Il-Kyoo Park
Session
Title: 617. Acute Myeloid Leukemia: Biology, Cytogenetics and
Molecular Markers in Diagnosis and Prognosis (News - Alert): Poster II
Date: Sunday,
December 7, 2014, 6:00 PM-8:00 PM PT
Location: North
Building, Hall E (Moscone Center)
About Tolero
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company
developing treatments to improve and extend the lives of patients with
serious oncological and hematological diseases. Our diverse pipeline
targets important biological drivers of blood disorders to treat
leukemias and anemia as well as important targets of drug resistance and
transcriptional control.
[ Back To TMCnet.com's Homepage ]
|
